Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-PMD22 PET Imaging in GI Tumors
NCT05937919Phase 1Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2023
- Primary completion
- Aug 2023
- Modality
- Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 1, open-label trial of 68Ga-PMD22 in gastrointestinal cancer (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: Dosimetric distribution of radiopharmaceuticals at 2 months and Standardized uptake value at 2 months. Status: unknown.
02
Drugs
68Ga-PMD22
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on NCT05937919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05937919.